Bladder Cancer

Quality of life, sexual outcomes and self-image should be considered before choosing a treatment option for muscle-invasive bladder cancer, an expert said.

From Oliva Munn and Christine Brinkley discussing their cancer to Donnie Iris returning to the stage after his experience with the disease, here is what’s happening in the oncology space this week.

The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic bladder cancer, the agency has announced.

A phase 2 trial showed that Trodelvy plus Keytruda had a high response rate with lasting responses, emphasizing “potential additive or synergistic effects,” an expert said.

Anktiva boosted responses to BCG treatment without affecting quality of life, research showed.

Treatment for muscle-invasive bladder cancer called dose-dense MVAC did not improve survival compared with chemotherapy alone, although one drug in the combination faces a shortage.

I had a friend who was diagnosed with the same bladder cancer as me, though our experiences were extremely different.

Some patients with metastatic bladder cancer and FGFR3 genetic alterations may benefit from Balversa, as it “represents a critical need,” an expert said.

The Food and Drug Administration will speed up their review of Enhertu for previously treated patients with certain HER2-positive solid tumors.

Urinary minimal residual disease-negative status was related to preventing the return of cancer when certain patients with bladder cancer received Adstiladrin.

Postsurgical Keytruda improved disease-free survival — but not overall survival — in patients with locally advanced, muscle-invasive bladder cancer.

Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.

Frontline treatment with Keytruda and Cabometyx produced responses with a manageable safety profile in patients with cisplatin-ineligible urothelial carcinoma, a type of bladder cancer.

The FDA amended its approval for Balversa for the treatment of patients with locally advanced or metastatic bladder cancer.

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta.

The Food and Drug Administration has approved Padcev plus Keytruda to treat patients with locally advanced or metastatic bladder cancer.

The FDA accepted a priority review for the supplemental Biologics License Application of Opdivo with chemotherapy for untreated patients with unresectable or metastatic bladder cancer.

The FDA has granted priority review for the Padcev-Keytruda combination in untreated patients with metastatic bladder cancer, according to a news release.

Analysis of molecular subtypes of muscle-invasive bladder cancer can predict if a tumor is likely to respond to chemotherapy before surgery but is not associated with differences in survival.

Balversa improved outcomes for patients with high-risk bladder cancer, but may only work for those with a certain genetic alteration, an expert explained.

For the first time, a drug combination (Padcev plus Keytruda) outperformed frontline chemotherapy for patients with locally advanced or metastatic urothelial carcinoma.

Adding Opdivo to a standard-of-care chemotherapy regimen in patients with unresectable or metastatic urothelial carcinoma improved progression-free and overall survival.

A recent phase 3 trial revealed that the primary endpoint was met with Keytruda for patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma.

Padcev plus Keytruda may improve survival outcomes for some patients with advanced urothelial cancer, according to preliminary data.

Balversa has been submitted to the FDA for approval to treat patients with locally advanced or metastatic urothelial carcinoma.

Patients with nonmetastatic node-positive bladder cancer may have similar survival rates whether they underwent treatment with surgery or radical dose radiotherapy.

From Eric Braeden announces that he is cancer free to Tom Jones dying from cancer, this is what’s happening in the oncology space this week.

Findings from the phase 3 ATLAS and ENVISION trials reveal a non-surgical way to possibly benefit patients with low-grade, intermediate- risk non-muscle invasive bladder cancer.

A phase 1 trial just launched, and will evaluate IO102-IO103 plus Keytruda in patients with bladder cancer whose disease is unresponsive to BCG therapy.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.